Takeda Pharmaceutical, a Japan-based drugs company, has agreed to buy one of its corporate venturing unit’s portfolio companies, Envoy Therapeutics, for up to $140m.
Takeda Ventures invested in Envoy’s $8m series A round in October 2009 and partnered with the developer of drugs for neurological and psychiatric diseases.
The other investors in the A round had been venture capital firm 5AM Ventures and Roche Venture Fund, the corporate venturing unit of the eponymous Switzerland-based drugs group.
Takeda had also extended…
